Transforming growth factor-β1 is constitutively secreted by chinese hamster ovary cells and is functional in human cells

Biotechnology and Bioengineering

Volumn 108, Issue 11, 2011, Pages 2759-2764

  Beatson, Richard ^a   Sproviero, Daisy ^a   Maher, John ^a   Wilkie, Scott ^a,b   Taylor Papadimitriou, Joyce ^a   Burchell, Joy M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Chinese hamster ovary cells; CHO; Recombinant proteins; TGF ; TGFbeta

Indexed keywords

ACADEMIC RESEARCH; CELL TYPES; CHINESE HAMSTER OVARY CELLS; CHO; CHO CELL; CLINICAL USE; CYTOKINES; HUMAN CELLS; IMMUNOLOGICAL EFFECTS; PHARMACEUTICAL INDUSTRY; PLEIOTROPIC EFFECTS; RECOMBINANT PROTEIN; TGFBETA; TRANSFORMING GROWTH FACTORS;

CLONING; PROTEINS;

CELLS;

GLYCOPROTEIN; RECOMBINANT PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; CELL CLONE; CELL SELECTION; CELL TYPE; CHO CELL; CONTROLLED STUDY; HUMAN; HUMAN CELL; NONHUMAN; PLEIOTROPY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION;

ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOLOGIC FACTORS; T-LYMPHOCYTES; TRANSFORMING GROWTH FACTOR BETA1;

CRICETINAE; CRICETULUS GRISEUS;

EID: 80053053397     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.23217     Document Type: Article

References (18)

1. Abe M, Harpel JG, Metz CN, Nunes I, Loskutoff DJ, Rifkin DB. 1994. An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal Biochem 216: 276-284.
2. Annes JP, Munger JS, Rifkin DB. 2003. Making sense of latent TGFbeta activation. J Cell Sci 116: 217-224.
3. Bäckström M, Link T, Olson FJ, Karlsson H, Graham R, Picco G, Burchell J, Taylor-Papadimitriou J, Noll T, Hansson GC. 2003. Recombinant MUC1 mucin with a breast cancer-like O-glycosylation produced in large amounts in Chinese-hamster ovary cells. Biochem J 376: 677-686.
4. Burchell JM, Poulsom R, Hanby A, Whitehouse C, Cooper L, Clausen H, Miles D, Taylor-Papdimitriou J. 1999. An alpha2, 3 sialyltransferase (ST3Gal I) is elevated in primary breast carcinomas. Glycobiology 9: 1307-1311.
5. Chatenoud L, Bach JF. 2006. Adaptive human regulatory T cells: Myth or reality? J Clin Invest V 116: 2325-2327.
6. Derynck R, Miyazono K. 2008. The TGF-β family. In: Derynck R, Miyazono K, editors. The TGFbeta family. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, p. 29.
7. Ferrari G, Cook BD, Terushkin V, Pintucci G, Mignatti P. 2009. Transforming growth factor-beta 1 (TGF-beta1) induces angiogenesis through vascular endothelial growth factor (VEGF)-mediated apoptosis. J Cell Physiol 219: 449-458.
8. Hannon GJ, Beach D. 1994. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 371: 257-261.
9. Kekow J, Reinhold D, Pap T, Ansorge S. 1998. Intravenous immunoglobulins and transforming growth factor beta. Lancet 351: 184-185.
10. Li CY, Suardet L, Little JB. 1995. Potential role of WAF1/Cip1/p21 as a mediator of TGF-beta cytoinhibitory effect. J Biol Chem 270: 4971-4974.
11. Li MO, Wan YY, Sanjabi S, Robertson A-KL, Flavell RA. 2006. Transforming growth factor-Beta regulation of immune responses. Annu Rev Immunol 24: 99-146.
12. Nakao A, Fujii M, Matsumura R, Kumano K, Saito Y, Miyazono K, Iwamoto I. 1999. Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. J Clin Invest 104: 5-11.
13. Omasa T, Onitsuka M, Kim WD. 2010. Cell engineering and cultivation of Chinese hamster ovary (CHO) cells. Curr Pharm Biotechnol 11: 233-240.
14. Pak SCO, Hunt SMN, Bridges MW, Sleigh MJ, Gray PP. 1996. Super CHOsA cell line capable of autocrine growth under fully defined protein-free conditions. Cytotechnology 22: 139-146.
15. Reinhold D, Perlov E, Schrecke K, Kekow J, Brune T, Sailor M. 2004. Increased blood plasma concentrations of TGF-beta isoforms after treatment with intravenous immunoglobultins (i.v.IG) in patients with multiple sclerosis. J Neuroimmunol 152: 91-194.
16. Rughetti A, Pellicciotta I, Biffoni M, Bäckström M, Link T, Bennet EP, Clausen H, Noll T, Hansson GC, Burchell JM, Frati L, Taylor-Papadimitriou J, Nuti M. 2005. Recombinant tumor-associated MUC1 glycoprotein impairs the differentiation and function of dendritic cells. J Immunol 174: 7764-7772.
17. Wahl SM, Wen J, Moutsopoulos N. 2006. TGF-beta: A mobile purveyor of immune privilege. Immunol Rev 213: 213-227.
18. Xu J, Lamouille S, Derynck R. 2009. TGF-beta-induced epithelial to mesenchymal transition. Cell Res 19: 156-172.